期刊文献+

端粒酶活性检测与非小细胞肺癌的相关性研究 被引量:7

Detection of telomerase activity associated with non-small cell lung cancer study.
下载PDF
导出
摘要 目的探讨端粒酶活性在非小细胞肺癌(NSCLC)组织中的表达,以了解其临床意义。方法采用端粒重复序列扩增法一酶联免疫(PCR-TRAP)检测70例肺癌手术患者癌组织中的端粒酶活性,并与70例肺部良性疾病患者对照组的检测结果进行比较。结果端粒酶活性在肺癌组中的阳性率明显高于对照组的阳性率,差异有显著性(P<0.01);Ⅲ期的阳性率明显高于Ⅰ期和Ⅱ期的阳性率,差异有显著性(P<0.05)。结论端粒酶活性检测对NSCLC的诊断具有鉴别意义,有一定的临床辅助价值。 Objective Discuses telomerase activity in the expression of NSCLC, to learn about their clinical significance. Methods Use PCR - TRAP detection of 70 cases of lung cancer patients'telomerase activity in cancer tissue, and 70 patients with benign lung disease and the results were compared. Results The telomerase activity in the lung cancer group was significantly higher than the positive rate, the difference was significant. 19 was significantly higher than in stages Ⅰ and Ⅱ, the positive rate, the difference was significant. Conclusion Detection of telomerase activity in the diagnosis of NSCLC differentiating, the clinical support a certain value.
出处 《临床和实验医学杂志》 2007年第4期43-43,45,共2页 Journal of Clinical and Experimental Medicine
关键词 端粒酶 非小肺癌 肿瘤标记 活性检测 相关性 诊断 Telomerase Non - small - cell lung carcinoma Tumor markers
  • 相关文献

参考文献5

二级参考文献25

  • 1宋丽华,宋现让,刘美芹,张锡芹,郑莉,李秀菊,刘蒲香.Ⅲ期Ⅳ期非小细胞肺癌预后影响因素分析[J].中华肿瘤杂志,2004,26(6):345-348. 被引量:17
  • 2[2]Shibuya K, Fujisawa T, Hoshino H, et al. Increased telomerase activity and elevated hTERTmRNA expression during multistage carcinogenesis of squamamous cell carcinoma of lung [J]. Cancer, 2001,92(6): 849-855.
  • 3[5]Gerwins P, Skoidenberg E, Claesson Welsh L. Function of fibroblast growth factor and VEGF and their receptors in angiogenesis[J]. Crit Rev Oncol Hematol,2000,34(3):85-194.
  • 4Kim NK, Hatyszek MA, Prowse KP,et al. Specific association of human telomerase activity with immortal cells and cancer.Science, 1994,266(5193) :2011.
  • 5Albanell J,Lonardo F,Rusch V, et al.High telomerase activity in primary lung cancer: association with increased cell proliferation rate and advanced stage.J Nail Cancer Inst, 1997,89(21) : 1609.
  • 6Mountain CF. Staging classification of lung cancer: a critical evaluation. Clin Chest Med, 2002, 23: 103-121.
  • 7Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem, 2002, 48: 1931-1937.
  • 8Foa P, Fornier M, Miceli R, et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers, 1999,14:92-98.
  • 9Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role. Chest,1995,108:163-169.
  • 10Foa P, Fornier M, Miceli R, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res, 1999,19:3613-3618.

共引文献32

同被引文献75

引证文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部